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Aim To determine whether matrix metalloproteinase-9 
(MMP-9) may be a useful adjunctive tool for predicting 
unfavorable biological behavior of papillary thyroid carci-
noma (PTC) by evaluating the expression profile and pro-
teolytic activity of MMP-9 in PTC by different techniques 
and correlating the findings with clinicopathological prog-
nostic factors.
Methods Immunohistochemical localization of MMP-9 
was analyzed with antibodies specific for either total or ac-
tive MMP-9. Activation ratios of MMP-9 were calculated by 
quantifying gel zymography bands. Enzymatic activity of 
MMP-9 was localized by in situ zymography after inhibit-
ing MMP-2 activity.
Results Immunostaining of total and active MMP-9 was 
observed in tumor tissue and occasionally in non-neoplas-
tic epithelium. Only active MMP-9 was significantly asso-
ciated with extrathyroid invasion, lymph-node metastasis, 
and the degree of tumor infiltration (P < 0.001, P = 0.004, 
and P < 0.001, respectively). Gelatin zymography revealed a 
correlation between the MMP-9 activation ratio and nodal 
involvement, extrathyroid invasion, and the degree of tu-
mor infiltration. In situ zymography showed that gelatinas-
es exerted their activity in tumor parenchymal and stromal 
cells. Moreover, after application of MMP-2 inhibitor, the re-
maining gelatinase activity, corresponding to MMP-9, was 
highest in cancers with the most advanced degree of tu-
mor infiltration.
Conclusions This is the first report suggesting that the 
evaluation of active MMP-9 by immunohistochemistry and 
determination of its activation ratio by gelatin zymography 
may be a useful adjunct to the known clinicopathological 
factors in predicting tumor behavior. Most important, in 
situ zimography with an MMP-2 inhibitor for the first time 
demonstrated a strong impact of MMP-9 activity on the 
degree of tumor infiltration during PTC progression.
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Papillary thyroid carcinoma (PTC) is the most common ma-
lignancy of the thyroid, with a rapid global rise in incidence 
in the recent decades. Despite its generally indolent be-
havior, a small proportion of PTC patients develop more 
aggressive forms of the disease. Several clinical and histo-
pathological parameters, such as sex, age, histologic grade, 
and tumor stage have been reported as useful in improv-
ing prognostic stratification (1). However, the prognosis of 
tumor behavior for individual patients with thyroid cancer 
can vary greatly, partly due to the marked clinical hetero-
geneity among such patients, even within a particular his-
tologic group. Therefore, it is important to understand the 
molecular mechanisms responsible for cancer develop-
ment, progression, and metastasis, and to establish novel 
strategies for predicting biological behavior of thyroid can-
cer and for clinical management of patients.
In cancer research, much interest has been devoted to al-
terations in expression grade and activity of various ma-
trix metalloproteinases (MMPs) and their corresponding 
inhibitors (2). MMPs are a family of zinc-dependent en-
dopeptidases with the capacity to degrade extracellular 
matrix proteins and basement membranes (3), and are 
therefore strongly implicated in multiple stages of can-
cer progression. Among the MMPs, a subset called gelati-
nases, consisting of MMP-2 (gelatinase A) and MMP-9 (ge-
latinase B), has gained the most attention in studies on 
the acquisition of invasive and metastatic tumor proper-
ties, as they degrade collagen IV, the major component 
of the basement membrane (4,5). Their proteolytic ac-
tivity is regulated at various levels, including expression, 
balance between amounts of enzymes and their inhibi-
tors, pericellular localization, and most importantly, la-
tent form activation. Namely, gelatinases are secreted as 
inactive proenzymes and are activated after cleavage of 
the pro-peptide domain of the molecule (6). MMP-9 is of 
special interest because its basal expression is normally 
low, whereas it is highly expressed in most human can-
cers in response to various growth factors and cytokines 
(7,8). It has been shown that MMP-9-deficient mice exhibit 
impaired metastasis formation and tumor growth (9). In 
this respect, up-regulation of MMP-9 expression in various 
types of human cancers contributes to the tumor progres-
sion, invasion, and metastasis (10-13).
There is much evidence demonstrating that MMP-9 is over-
expressed in various tumor types when compared to nor-
mal tissue (14-16). On the other hand, this protein has not 
been widely investigated in thyroid tumors and there are 
still some controversies regarding its usefulness as a mark-
er for diagnosis or prognosis of these tumors (17-21). More-
over, the ratio of active-to-total MMP-9 and the precise lo-
calization of enzymatic activity in thyroid tissue have not 
yet been investigated. To localize MMP-9 expression in PTC 
and corresponding non-tumor tissue, we used two com-
mercial antibodies that recognize either both pro-active 
and active or only active form of MMP-9 for immunohis-
tochemistry. To our knowledge, active form of MMP-9 has 
not been immunohistochemically evaluated on thyroid 
tissue sections previously. We also used gelatin zymog-
raphy, which is a sensitive, quantifiable assay to analyze 
pro-active and active form of MMP-9, and sensitive dye-
quenched gelatin (DQ-gelatin) in situ zymography with a 
selective MMP-2 inhibitor to localize the gelatinase activ-
ity corresponding to MMP-9 in tissue. Thus, we explored 
the expression profiles, activation ratio, and localization of 
MMP-9 activity in tissue sections of papillary thyroid carci-
nomas and correlated the findings with clinicopathologi-
cal prognostic factors with the aim of determining wheth-
er MMP-9 may be a useful adjunctive tool for predicting 
unfavorable biological behavior of PTC.
MaTerIal anD MeThoDS
Participant selection and clinical data
Thyroid cancer tissues were obtained at thyroidectomy 
from 120 consecutive patients surgically treated for PTCs at 
the Center for Endocrine Surgery, Clinical Center of Serbia, 
Belgrade between 2009 and 2012. The study was approved 
by the Ethics Committee at the Center for Endocrine Sur-
gery and informed consent was obtained where required.
All specimens were reviewed by a single pathologist, who 
confirmed the diagnosis of PTC according to the World 
Health Organization classification of thyroid malignancy 
(22), identified the histological variant of the tumor, divid-
ed fresh tissue into portions, and classified the specimens. 
A total of 120 routinely processed, formalin-fixed, and par-
affin embedded PTC specimens (with adjacent non-tumor 
tissue, when present) and 32 fresh tissue samples (paired 
tumor and non-tumor thyroid tissues from the contralat-
eral thyroid lobe) obtained from a cohort of 120 PTC pa-
tients were included in this study. All fresh tissue samples 
obtained immediately after thyroidectomy were snap-fro-
zen in liquid nitrogen and stored at -80 °C to be used for 
gelatin zymography analysis. At the same time, some of 
these fresh tissue samples (18 of 32) were fixed in alcohol 
and embedded in paraffin for evaluation of gelatinolyt-
ic activity by DQ in situ zymography.
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Formalin-fixed sections from all 120 PTCs were used for 
immunohistochemical studies. Of these samples, 62 were 
stained for both total and active MMP-9. The remaining 58 
samples were evaluated for total MMP-9 (n = 43) or active 
MMP-9 (n = 15), giving 105 and 77 samples for total and ac-
tive MMP-9, respectively.
Before the study, all tissue specimens were reexamined 
after hematoxylin-eosin staining by a board-certified pa-
thologist for confirmation of the pathologic diagnosis. 
Moreover, during the histopathological review, 73 cases 
were subsequently reevaluated for the degree of tumor 
infiltration, as described previously (23): group A – totally 
encapsulated tumors (n = 30); group B – non-encapsulated 
tumors without thyroid capsule invasion (n = 16); group C 
– tumors with thyroid capsule invasion (n = 10); and group 
D – tumors with extrathyroid extension (n = 17). Informa-
tion concerning sex, age, lymph node metastasis involve-
ment, extrathyroid invasion, and tumor size was retrieved 
by reviewing the pathology reports.
Tissue extraction
To minimize variation, each pair of thyroid carcinoma and 
matched normal tissue was extracted and assayed at the 
same time. Tissue samples were cut into small pieces ho-
mogenized in 1 mL of cold extraction buffer (20 mM Tris 
HCl, 137 mM NaCl, 10% glycerol, 1% nonidet P-40, 2 mM 
EDTA) and then rotated at 11 000 g for 20-minute at 4°C 
in an Eppendorf centrifuge (Eppendorf, Hamburg, Ger-
mamy). The supernatant was aliquoted and the protein 
content was determined using a BCA Protein Assay Kit 
(Pierce Biotechnology, Rockford, IL, USA).
Gelatin zymography
The presence of active and latent forms of gelatinases was 
analyzed in 32 tissue samples by zymography in non-re-
ducing conditions on 8% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) containing 1% 
gelatin. Sample volumes were adjusted to obtain a uniform 
protein content of 50 µg per lane. After electrophoresis, 
the gels were washed twice in 2.5% Triton-X and five times 
in water. The gels were then incubated overnight at 37°C in 
reaction buffer (5 mM CaCl2, and 50 mM Tris-HCl buffer, pH 
7.0). Gelatinase activity was visualized by staining the zy-
mograms with Coomassie brilliant blue (0.25% Coomass-
ie brilliant blue G250, 30% acetic acid, 10% methanol, all 
from Sigma-Aldrich, St Louis, MO, USA) and destaining 
in acetic acid-methanol-dH2O (1:3:6) for 1-2 hours. 
Gelatinolytic activity was observed as a clear band of di-
gested gelatin against a blue background. To confirm that 
the visualized zones of lysis were due to MMP activity, se-
lected duplicate gels were incubated using either MMP-2 
inhibitor (13.7 nM ARP-100) or 20 mM EDTA.
The MMP-9 activation ratio was calculated from the data 
obtained by densitometric analysis of the 93 kDa and 83 
kDa bands corresponding to latent and active forms of 
MMP-9, respectively, using TotalLab TL120 software (Non-
linear Dynamics Ltd, Newcastle, UK).
Immunohistochemistry
A total of 105 PTC sections were stained for total MMP-9, 
60 out of which were classified as classical PTC and 45 as 
the follicular variant (24). Forty-eight classical PTCs and 29 
samples of the follicular variant were also stained for acti-
vated MMP-9. Immunohistochemistry was performed as 
described before (25). The sections were incubated with di-
luted primary antibodies, ie, mouse anti-human MMP-9 ac-
tivated MCA2736, recognizing the ~ 83 kDa active form of 
MMP-9 (AbD Serotec, Kidlington, UK) and mouse monoclo-
nal 56-2A4, recognizing both pro-active and active forms of 
MMP-9 (Abcam, Cambridge, UK). The signal was enhanced 
with the avidin-biotin-peroxidase complex (Vectastain ABC 
kit, Vector Laboratories, Burlingame, CA, USA), followed by 
visualization of the reaction with 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) solution (Peroxidase Substrate Kit, 
Vector Laboratories, Burlingame, CA, USA). The slides were 
counterstained with hematoxylin and examined using an 
Axio Imager 1.0 microscope (Carl Zeiss, Jena, Germany) with 
a Canon A640 Digital Camera System (Tokyo, Japan). Nega-
tive controls were incubated with PBS in place of the prima-
ry antibody and no positive staining was observed.
The tumor sections were examined by two individuals 
(with no knowledge of the clinical findings) for staining in-
tensity and distribution of immunoreactivity within a sin-
gle tissue section. Scoring of epithelial staining was evalu-
ated separately for tumor and the surrounding non-tumor 
tissues. Thus, the staining was graded for total MMP-9 us-
ing an empirical semiquantitative system as reported pre-
viously (25), in brief: 0) no reaction or focal weak/moderate 
reaction; 1) strong focal or diffuse weak reaction; 2) moder-
ate diffuse reaction; 3) intense diffuse reaction. The stain-
ing for active MMP-9 was graded as follows: 0) no reaction; 
1) weak reaction; 2) moderate reaction; 3) intense reaction. 
Immunohitochemical staining was evaluated by indepen-
dent observers, with high concordance. When there was 
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doubt between two scores, the observers reexamined the 
slide together in order to establish a consensus.
In situ zymography
In situ zymography was performed as described by Hadler-
Olsen et al (26). In brief, alcohol-fixed, paraffin-embedded 
tissue sections were deparaffinized in xylene and rehydrat-
ed in graded alcohol baths. Then tissue specimens were 
washed twice with PBS, overlaid with a solution of 50 μg/mL 
dye-quenched gelatin (DQ gelatin; Molecular Probes, Ther-
mo Fisher Scientific, Wyman, MA, USA) in reaction buffer and 
incubated in a dark humidity chamber at 37°C for 2 hours. 
After that, the sections were rinsed in PBS baths (2 × 5 min-
utes) and overlaid with DAPI containing antifade solution 
(S7113, Merck Milliporem, Billerica, MA, USA) to counterstain 
the nuclei. Specimens were fixed with neutral buffered for-
malin, and green fluorescence indicative of gelatinase activ-
ity was observed under a 10 × objective of the fluorescence 
microscope (Axio Imager 1.0 microscope with AxioCam HR 
monochrome camera, Carl Zeiss, Jena, Germany).
The level of autofluorescence on the tissue sections was 
evaluated by substrate incubation on control sections 
from each tissue at -20°C for 2 hours. To verify the contri-
bution of metalloproteinases, control slides were preincu-
bated with 20 mM EDTA for 1 hour. In addition, to verify the 
contribution of the two most effective gelatinolytic MMPs, 
MMP-2 and indirectly MMP-9, slides were coated with sub-
strate containing MMP-2 inhibitor ARP-100 (sc 203522, 
Santa Cruz Biotechnologies, Santa Cruz, CA, USA) in a final 
concentration of 13.7 nM. For most of the tissues, at least 
two independent experiments were performed.
Statistical analysis
Statistical analysis was performed with the software pack-
age SPSS 12.0.1 (SPSS Inc., Chicago, IL, USA) for Windows. 
The association between immunohistochemical results 
(positive immunostaining) for each antibody and clinico-
pathological data was determined using 2-tailed χ2 or Fish-
er exact tests where appropriate, as well as the Spearman 
rank correlation test. The Mann-Whitney U test was used 




Immunohistochemical staining revealed that total MMP-9 
was present in the majority of tumors (Figure 1), while the 
FIGure 1. number and percentage of cases stained for active 
and total matrix metalloproteinase-9 (MMP-9) in papillary 
thyroid carcinoma (PTC) and nontumor tissues (nT).
FIGure 2. representative micrographs of immunostaining for 
total and active matrix metalloproteinase-9 (MMP-9) in thyroid 
tissue samples. (a) Moderate diffuse immunoreaction for total 
MMP-9 in one case of encapsulated papillary thyroid carci-
noma (PTC). (b) negative immunostaining for active MMP-9 in 
the same case. (c) Strong diffuse MMP-9 positivity in a case of 
PTC with extrathyroid invasion. (d) Strong staining for active 
MMP-9 in a case of PTC with extrathyroid invasion.
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majority of peritumoral tissues remained immunonega-
tive. Active MMP-9 was present in 56% of follicular epithe-
lial cells of PTC cases (Figure 1). When present, the staining 
was mostly cytoplasmic and sometimes had a granular ap-
pearance. In peritumoral tissue, active MMP-9 was detect-
ed in only one sample. Positivity for both total and active 
MMP-9 was also evident to a varying degree in the stromal 
compartment, inflammatory cells, myo/fibroblast-like cells, 
and endothelial cells (data not shown).
association with clinicopathological parameters
Immunoexpression of total MMP-9 in PTC samples was not 
significantly correlated with any clinicopathological feature. 
On the other hand, immunoexpression of active MMP-9 
was positively correlated with lymph node metastases, ex-
trathyroid invasion, and degree of neoplastic infiltration, as 
indicated both by χ2 test (or Fisher exact test when neces-
sary) and Spearman’s correlation analysis (Table 1). A corre-
lation with patient age at diagnosis was shown with Spear-
man’s analysis, but the χ2 test failed to confirm it, and no 
correlation was found between active MMP-9 and sex or 
tumor size. An example of total and active MMP-9 immu-
noexpression in PTCs with different degrees of neoplastic 
infiltration is given in Figure 2.
Gel-zymography
Samples were analyzed for MMP-9 activation by gelatin 
zymography. Bands corresponding to latent MMP-9 and 
MMP-2 were clearly detected in all tumor samples, where-
as active forms of MMP-9 and MMP-2 showed less distinct 
bands or no bands in some samples (Figure 3). The levels 
of MMP-2 and MMP-9 were significantly higher in carcino-
Table 1. Correlation between total and active matrix metalloproteinase-9 (MMP-9) immunohistochemical expression and clinico-
pathological features in papillary thyroid carcinoma (PTC) patients*
Total MMP-9 active MMP-9












patients <45 y  8 42 0.448 0.144 20 16 0.059 0.034
patients ≥45 y 12 43 14 27
Sex:
male  6 15 0.214 0.100  5 10 0.347 0.126
female 14 70 29 33
Tumor size:
<2 cm  9 27 0.261 0.977 13 10 0.153 0.162
≥2 cm 11 58 21 33
lymph node metastasis:
no 19 67 0.185 0.246 31 31 0.018 0.004
yes  1 17  2 12
extrathyroid invasion:
no 14 63 0.708 0.067 31 24 <0.001 <0.001
yes  6 22  1 19
Degree of neoplastic infiltration:§
A  9 16 0.136 0.100 23  7 <0.001 <0.001
B  1 11  4 12
C  2  4  3  7
D  1 11  2 15
*among the patients included in statistics for both total and active MMP-9, one had unknown lymph node metastasis status and was therefore 
excluded from this category. For active MMP-9, in the category extrathyroid invasion, two samples were excluded because of missing data for tumor 
invasion. out of the 73 cases that were reexamined for degree of tumor infiltration (23), 55 were included in the subsequent analyses for total MMP-9 
and all 73 reexamined for active MMP-9.
†Immunostainings: negative – score 0; positive – scores 1, 2 and 3.
‡bolded numbers indicate statistical significance at P < 0.05 level.
§Degree of neoplastic infiltration: a – totally encapsulated tumors; b – non-encapsulated tumors without thyroid capsule invasion; C – tumors with 
thyroid capsule invasion; D – tumors with extrathyroid extension.
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mas than in peritumoral tissue, irrespective of MMP type or 
activity state. The specific MMP-2 inhibitor ARP-100 almost 
completely inhibited MMP-2 on the SDS-gel zymogram, 
thus confirming its identity, but had almost no effect on 
MMP-9 in the applied concentration of 13.7 nM. The gener-
al metalloproteinase inhibitor, EDTA, completely abolished 
the reaction in SDS gel zymography (Figure 3). These data 
verified that these enzymes were all metalloproteinases.
Computer-assisted image analyses of the intensity of pro-
teolytic bands allowed separate quantification of pro-en-
zyme and active form of the enzyme. These results were 
used to calculate the ratio of active-to-total MMP-9 for each 
sample and to correlate it with clinicopathological charac-
teristics of PTC. The activation ratio of MMP-9 was signifi-
cantly higher in PTC samples presenting with extrathyroid 
invasion and lymph node metastases than in those with-
out them (P < 0.001 and P = 0.006, respectively).
When we associated the level of MMP-9 activation with 
the degree of neoplastic infiltration, a significant difference 
was found between the activation ratio of the fourth group 
(D) and any of other three, in other words, when group D 
was compared to group A, group B, or group C, respective-
ly (P = 0.001, P = 0.008, and P = 0.008) (Figure 4). In addition, 
Spearman analysis revealed a positive correlation between 
the activation levels of MMP-9 and the degree of neoplas-
tic infiltration (P < 0.001, rs = 0.624). However, there was no 
significant association with the age of patients or tumor 
size (data not shown).
When we analyzed the correlation between the results 
for MMP-9 activation ratio obtained by zymography and 
active MMP-9 by immunohistochemistry for 32 matched 
cases of tumor, we found a positive relationship between 
zymography results and immunohistochemical scores 
(rs = 0.584, P < 0.001).
Detection of gelatinolytic activity by In situ 
zymography
All PTC tissues showed strong to moderate gelatinase activ-
ity in the follicular epithelium and, occasionally, in stromal 
cells (myo/fibroblast-like cells, endothelial cells, inflamma-
tory cells, adipocytes). A duplicate tissue section incubated 
in the presence of 20 mM EDTA, a general inhibitor of MMP 
FIGure 3. an example of the gelatin zymograms used for 
matrix metalloproteinase-9 (MMP-9) quantitation by den-
sitometry. Gelatin degradation was monitored by sodium 
dodecyl sulfate (SDS)-8% polyacrylamide gel electrophoresis 
(PaGe) and Coomassie blue staining. Gelatinolytic bands of 92, 
83, 68, and 62 kDa corresponded to proMMP-9, active MMP-9, 
proMMP-2, and active MMP-2, respectively: nT – non-tumoral 
thyroid tissue, ei – extrathyroid invasion. lane 1, tissue extract 
of papillary thyroid carcinoma (PTC) sample without extrathy-
roid invasion (ei-). lane 2, paired non-tumor tissue from the 
same patient. lanes 3 and 4, tumor and paired non-tumor 
tissue extract from another PTC sample with extrathyroid inva-
sion (ei+). lane 5, a duplicate gel of sample (ei+) incubated in 
the presence of 13.7 nM arP-100, a general inhibitor of MMP-2 
activity. lane 6, the same sample incubated with 10 mM eDTa.
FIGure 4. activation ratio of promatrix metalloproteinase-9 
(MMP-9) in papillary thyroid carcinoma (PTC) measured by 
densitometric analysis of zymographic gels. The activation 
ratios of MMP-9 (proMMP-9) were calculated by dividing the 
density of the band for active MMP-9 by the sum of the den-
sity of the bands for both latent and active forms. The boxes 
represent the interquartile range and vertical lines show the 
range of observations. The midlines of boxes give the median 
values of activation ratios. a, b, C, D are groups of PTC patients 
with the following degrees of neoplastic infiltration: a – totally 
encapsulated carcinomas; b – non-encapsulated tumors 
without thyroid capsule invasion; C – tumors with thyroid 
capsule invasion; D – tumors with extrathyroid invasion. lnM+ 
are carcinomas with lymph node metastasis, lnM – tumors 
without metastases; ei + and ei- are tumors with and without 
extrathyroid invasion, respectively.
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activity, exhibited almost no specific gelatinolytic activity. 
Normal thyroid follicular epithelial cells generally had neg-
ligible gelatinase activity. The difference between normal 
and cancerous tissues was obvious.
In addition, we analyzed MMP-9 activity in PTC tissues 
showing various degrees of tumor infiltration. The PTCs ex-
hibited prominent gelatinolytic activity, which was hetero-
geneous within a given tumor and did not differ substan-
tially among different categories of tumor invasion (Figure 
5 a2, b2, c2). Gelatinolytic activity was greatly diminished 
on sections incubated with 13.7 nM ARP-100, the MMP-2 
inhibitor (Figure 5 a3, b3, c3), when compared with the 
control sections without inhibitor (Figure 5 a2, b2, c2). This 
indicates that ARP-100 at 13.7 nM can prevent MMP-2 ac-
tivity, so almost all the breakdown of DQ gelatin may be 
attributed to the enzymatic activity of other gelatinolytic 
enzymes, ie, to MMP-9. After incubation with ARP-100, 
the level of green fluorescence compatible with ge-
latinolytic activity in encapsulated PTC (Figure 5, a3) 
was almost abolished. It may be concluded that gelatinase 
activity in most encapsulated PTCs mainly resulted from 
MMP-2, because activity was largely diminished by the in-
hibitor. It was also assumed that the remaining activity was 
predominantly due to MMP-9, which increased gradually 
in tumors with a greater degree of tumor infiltration (Fig-
ure 5, b3 and c3).
The results of in situ zymography were generally in correla-
tion with previously used methods. The relative differences 
in fluorescence intensity observed by in situ zymography 
after applying ARP 100 in most cases showed the staining 
trend of active MMP-9 observed by immunohistochemis-
try and active to total MMP-9 ratio calculated by gel zy-
mography. The discrepancies between results for in situ 
zymography and immunohistochemistry were confined 
to four cases, all belonging to groups A and B.
DISCuSSIon
The study provides the first analysis of immunohistochem-
ical expression of active MMP-9 in thyroid tissue sections 
and its relation to clinicopathological parameters of PTC. 
We showed that the production of total MMP-9 was great-
er in cancer than in the corresponding non-tumor thyroid 
tissue, unlike the report of Korem et al (18). In addition, our 
results revealed that total MMP-9 immunoreactivity was 
not correlated with any clinicopathological factor, which 
might suggest that mere overexpression of MMP-9 does 
not lead to more aggressive behavior of PTC. This is in con-
trast with previous reports (19,21,27,28), where abundant 
expression of MMP-9 correlated significantly with invasion 
and metastasis of thyroid carcinomas.
This study compared histological expression patterns of 
both total and active MMP-9 in PTC tissue samples in re-
lation to some clinicopathological parameters. The novel 
finding was that active MMP-9 occurred almost only in can-
cer tissue and was correlated with age, presence of lymph 
node metastasis, extrathyroid invasion, and the degree of 
tumor infiltration, suggesting that MMP-9 was activated in 
tumor cells and that this was associated with aggressive 
tumor behavior in PTC.
To confirm the obtained immunohistochemical results of 
MMP-9 expression profiles and to find out whether there 
are any differences in the amount and degree of conver-
sion of latent MMP-9 to its active counterpart between 
PTCs divided into distinct clinicopathological groups, we 
performed gelatin zymography. This procedure showed 
FIGure 5. In situ zymography of gelatinase activity in papil-
lary thyroid carcinomas with different degrees of neoplastic 
infiltration. (a) encapsulated carcinoma; (b) non-encapsulated 
tumor without thyroid capsule invasion; (c) tumor with 
extrathyroid extension. horizontal layers (1-3) represent the 
consecutive sections of the same tumor. left column, image 
of the hematoxylin/eosin stained papillary thyroid carcinoma 
(PTC) tissue sections. Middle column, distribution of gelati-
nolytic activity in serial tissue sections of the same areas 
of cases as the left column, subjected to fluorescent in situ 
zymography. Intense fluorescence was observed predomi-
nantly in the follicular epithelium, but also in some cells of 
tumoral stroma. right column, matrix metalloproteinase-2 
inhibitor-treated subsequent sections of the same cases as left. 
Decreased gelatinolytic activity is seen in thyrocytes and the 
stromal compartment.
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distinct bands of both latent and active MMP-9 in tumor 
extracts but vague bands in non-tumor extracts. The levels 
of active MMP-9 in our series of PTC tissue extracts were 
significantly higher in tumor tissues than in non-tumor tis-
sues. To date, only the study of Maeta et al (19) analyzed 
the production and activation of MMP-9 in thyroid tissue 
by zymography, and both were greater in cancer tissue 
than in the corresponding non-tumor tissue. Our results 
extend these findings by demonstrating that there is not 
only more pro-active (latent) and active MMP-9 in PTC than 
in adjacent non-tumor tissue, but that the ratio of active to 
total MMP-9 is significantly elevated in PTC. Furthermore, 
this ratio increased substantially in tumors expressing a 
more aggressive phenotype, ie, in cases with extrathyroid 
invasion compared to those lacking these features. Patel 
et al (29) also reported that the activation ratio of MMP-9 
was significantly elevated in malignant tissues compared 
to adjacent normal tissues in patients with oral squamous 
cell carcinoma, while the opposite was found for colorec-
tal cancer and early-stage lung cancer, where the ratio was 
lower in tumor than in normal tissue (30,31).
Although gelatin zymographic analysis allows quantifi-
cation of active and the pro-enzyme form of gelatinases, 
it does not provide information at the cellular level. This 
was overcome with the introduction of in situ zymogra-
phy with the quenched fluorogenic substrate DQ-gelatin, 
which enables visualization of gelatinases activity in tissue 
sections. To our knowledge, in situ zymography on thyroid 
carcinoma tissue has been reported only by Nakamura et al 
(32). Unlike us, they used film in situ zymography method 
on frozen tissue sections, demonstrating that gelatinolytic 
activity was confined to follicular epithelial tumor cells. Our 
method employing DQ gelatin provided more detailed in-
formation on the localization of gelatinolytic activity, not 
only in follicular epithelial cells, but also within stroma, in-
dicating that both compartments had the potential to play 
a role in biological behavior of PTC.
Finally, in order to more adequately define the source of 
gelatinolitic activity detected with DQ gelatin zymography 
on PTC tissue sections, we used a selective MMP-2 inhibi-
tor. After selective inhibition of MMP-2 activity on a section 
of encapsulated PTC cases, the remaining gelatinase activ-
ity observed by in situ zymography was greatly diminished 
in most cases, suggesting a predominance of MMP-2 activ-
ity in these tumors, ie, almost an absence of MMP-9 activ-
ity. These results taken together with immunohistochemi-
cal staining of the same cancer areas for total and active 
MMP-9, suggested divergence between enzyme distribu-
tion and activity, either because MMP-9 is present mainly 
in its latent forms in most encapsulated PTCs, or because 
the active form is inhibited by endogenous antagonists. 
On the other hand, gelatinolitic activity was only slightly 
reduced by the MMP-2 inhibitor in tumors with the most 
advanced degree of infiltration, which may indicate a 
greater role for MMP-9 within these tumors. These cases 
also frequently exhibited a positive immunoreaction for 
active MMP-9 and efficient activation of MMP-9, as deter-
mined by gel zymography.
To conclude, the present study is the first report suggest-
ing that evaluation of active MMP-9 by immunohistochem-
istry and the MMP-9 activation ratio by gelatin zymogra-
phy may be a useful adjunct to known clinicopathological 
factors in predicting tumor behavior. Most important, in 
situ zymography with an MMP-2 inhibitor for the first time 
demonstrated a strong impact of MMP-9 activity on the 
degree of tumor infiltration during PTC progression.
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